ClinicalTrials.gg
RecruitingNCT07220096Updated Oct 6, 2026

Registry Trial and Needs Assessment of Patients With Young-onset Lung Cancer: Impact of a Dedicated Care Program on Patient Experience and Outcomes

An observational study in Lung Cancer, sponsored by M.D. Anderson Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by M.D. Anderson Cancer Center · Observational

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
75
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 162 studies in Lung Neoplasms by M.D. Anderson Cancer Center — 22 open to participants now, 48 under way, 2 of them phase 3. Lung Neoplasms · M.D. Anderson Cancer Center.

Planned enrollment
24th of 37
75 · median 127
Started
2025
with 1 other
Observational
37 of 162
6 open now
Primary completion
2029-05
later than 44 of 47 live
Registered
161st of 162
by date

Among the 162 studies in Lung Neoplasms by M.D. Anderson Cancer Center, this one is the 24th largest by planned enrollment of the 37 observational ones that give a count, is one of 2 that started in 2025, is one of 37 observational ones, reaches primary completion later than 44 of the 47 other live ones, and was the 161st registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

22 of the 162 studies in Lung Neoplasms by M.D. Anderson Cancer Center are open now, in 1 country. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 22 open studies →

Where they have run

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 162 studies in Lung Neoplasms by M.D. Anderson Cancer Center, or all of them as a file.
02

Study summary

The goal of this research study is to learn about:

The effect of enrolling in the YOLC program on patient satisfaction with care provided,

The needs of patients younger than 50 with lung cancer and their family, and

The impact of participating in peer support networks on these patients.

Read the detailed description

Primary Objectives:

  1. To determine whether enrollment in a dedicated program (YOLC) results in improved patient satisfaction with care provided.
  2. To characterize the distinct needs of patients under age 50 diagnosed with lung cancer as well as those of their families, and how these needs may change over time throughout the care pathway.
  3. To evaluate the impact of participation in peer support networks and whether it has a beneficial effect on the primary and secondary endpoints.

Secondary Objectives:

  1. To determine whether enrollment in a dedicated program (YOLC) results in improved patient satisfaction with care provided.
  2. To characterize the distinct needs of patients under age 50 diagnosed with lung cancer as well as those of their families, and how these needs may change over time throughout the care pathway.
  3. To evaluate the impact of participation in peer support networks and whether it has a beneficial effect on the primary and secondary endpoints.
  4. Overall survival, defined by time from diagnosis to death from any cause
  5. Clinical trial enrollment, defined by participation in any therapeutic clinical trial related to lung cancer treatment after diagnosis
  6. Completion of multi-disciplinary consultations, defined by patients completing consultations with at least one other specialist other than a thoracic medical oncologist or thoracic surgeon from time of initial consultation for the YOLC Program
  7. Quality of life, as defined by FACT-LUNG
  8. Financial toxicity, as defined by patient-reported financial burden, including out-of-pocket costs, insurance coverage issues, and impact of overall financial well-being (measured using validated financial toxicity scale such as COST-FACIT
03

Conditions studied

  • Lung Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

MD Anderson

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age greater than 18 years and under 50 years
  • Histologic confirmation of NSCLC
  • Able to complete an English-language survey independently or with the assistance of a native-language interpreter
  • Pregnant women- may be enrolled due to age range of subjects. (Low risk)

Exclusion criteria

Exclusion Criteria:

  • Medical, psychiatric, cognitive, or other conditions that compromise the patient's ability to understand the patient information, to give , to comply with the study protocol or to complete the study.
  • The following special patient population will be excluded from study group:

    • Individuals who are not yet adults (infants, children, teenagers)
    • Prisoners
    • Cognitively-impaired adults
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
75 participants (estimated)
Patient registry
No

Groups and cohorts

  • Assessment of Patients with Young-Onset Lung Cancer

    This is a registry trial enrolling participants with NSCLC diagnosed and histologically confirmed prior to the age of 50 years identified. Each participant will participate in an intake survey as well as periodic recurring surveys to provide feedback to the YOLC Program, to elucidate the individual participant's care needs, and to assess changes in personal goals, wellness, financial impact, and family support over time

    Other: Survey

Interventions

  • OtherSurvey

    Participants will complete an intake survey and repeat surveys at the following time points: * Baseline * 3 months * 6 months * 9 months * 12 months * 18 months * 24 months * 36 months * 48 months * 60 months

06

What researchers measure

Primary outcomes

  1. Participant satisfaction with care

    Assessed via validated survey instruments (e.g., FACT-L, COST-FACIT). • Focus on detecting even small changes in survey responses over time (baseline, 3, 6, 9, 12 months, etc.).

    Time frame: Through study completion; an average of 5 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for May 2029, 44 months after the start.

Of 592 non-industry observational studies under Lung Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 162. This study's planned 44 months is below that.

Counting every sponsor, half of 682 studies reached it within 57 months; a quarter within 25 and three quarters within 135.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2025
First posted
Oct 23, 2025
StartActual
Sep 25, 2025
Primary completionEst.
May 31, 2029
CompletionEst.
May 31, 2031
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07220096
Responsible party
Sponsor
First posted
Oct 23, 2025
Start date
Sep 25, 2025
Primary completion
May 31, 2029 (estimated)
Completion
May 31, 2031 (estimated)
Last update
Oct 6, 2026

Study contacts

Eric Singhi, MD
Contact
eksinghi@mdanderson.org
713-745-2263
Eric Singhi, MD
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion